JPWO2025005306A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2025005306A5
JPWO2025005306A5 JP2025509007A JP2025509007A JPWO2025005306A5 JP WO2025005306 A5 JPWO2025005306 A5 JP WO2025005306A5 JP 2025509007 A JP2025509007 A JP 2025509007A JP 2025509007 A JP2025509007 A JP 2025509007A JP WO2025005306 A5 JPWO2025005306 A5 JP WO2025005306A5
Authority
JP
Japan
Prior art keywords
cov
sars
pharmaceutical composition
composition according
onset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2025509007A
Other languages
English (en)
Japanese (ja)
Other versions
JP7674711B1 (ja
JPWO2025005306A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2024/035560 external-priority patent/WO2025005306A1/ja
Publication of JPWO2025005306A1 publication Critical patent/JPWO2025005306A1/ja
Priority to JP2025064259A priority Critical patent/JP2025108531A/ja
Application granted granted Critical
Publication of JP7674711B1 publication Critical patent/JP7674711B1/ja
Publication of JPWO2025005306A5 publication Critical patent/JPWO2025005306A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2025509007A 2023-10-05 2024-10-04 ウラシル誘導体を含有する医薬組成物 Active JP7674711B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064259A JP2025108531A (ja) 2023-10-05 2025-04-09 ウラシル誘導体を含有する医薬組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2023173420 2023-10-05
JP2023173420 2023-10-05
JP2024096866 2024-06-14
JP2024096866 2024-06-14
PCT/JP2024/035560 WO2025005306A1 (ja) 2023-10-05 2024-10-04 ウラシル誘導体を含有する医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064259A Division JP2025108531A (ja) 2023-10-05 2025-04-09 ウラシル誘導体を含有する医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2025005306A1 JPWO2025005306A1 (https=) 2025-01-02
JP7674711B1 JP7674711B1 (ja) 2025-05-12
JPWO2025005306A5 true JPWO2025005306A5 (https=) 2025-06-04

Family

ID=93938355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2025509007A Active JP7674711B1 (ja) 2023-10-05 2024-10-04 ウラシル誘導体を含有する医薬組成物
JP2025064259A Pending JP2025108531A (ja) 2023-10-05 2025-04-09 ウラシル誘導体を含有する医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064259A Pending JP2025108531A (ja) 2023-10-05 2025-04-09 ウラシル誘導体を含有する医薬組成物

Country Status (4)

Country Link
JP (2) JP7674711B1 (https=)
AU (1) AU2024307335A1 (https=)
TW (1) TW202523309A (https=)
WO (1) WO2025005306A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552872A1 (en) * 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
JP7624093B2 (ja) * 2022-04-08 2025-01-29 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物

Similar Documents

Publication Publication Date Title
JP2024071370A5 (https=)
JP2024516371A5 (https=)
JPWO2023054292A5 (https=)
JP2023535701A5 (https=)
JP2023002662A5 (https=)
JP2023166406A5 (https=)
JP2020507589A5 (https=)
JP2024170583A5 (https=)
CN114786659A (zh) 用于治疗汉坦病毒感染的mek抑制剂
JP2021521118A5 (https=)
JPWO2023054732A5 (https=)
EA020283B1 (ru) Средство для профилактики и лечения высокопатогенных инфекционных заболеваний
JP2022522694A5 (https=)
JP2024541569A5 (https=)
JP2023109937A5 (https=)
JPWO2023195530A5 (https=)
JP2023520323A5 (https=)
JP2025508656A5 (https=)
JP2024170457A5 (https=)
BR112022020020A2 (pt) Métodos de tratamento da doença do coronavírus 2019
EA028541B1 (ru) Способ лечения и профилактики заболеваний, вызываемых (+)рнк-содержащими вирусами
JPWO2025005306A5 (https=)
CN1160081C (zh) 用hiv蛋白酶抑制剂因地那夫和逆转录酶抑制剂3tc,以及任选的azt、ddi或ddc,对hiv感染进行组合治疗
JP2019536778A5 (https=)
JP2008521934A5 (https=)